K-L Kolho1, T Ruuska, E Savilahti. 1. Hospital for Children and Adolescents, University of Helsinki, Box 281, FIN-00029 HYKS, Helsinki, Finland. kaija-leena.kolho@helsinki.fi
Abstract
UNLABELLED: Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy. CONCLUSION: adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.
UNLABELLED: Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy. CONCLUSION: adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.
Authors: Marat V Khodoun; Richard Strait; Laura Armstrong; Noriko Yanase; Fred D Finkelman Journal: Proc Natl Acad Sci U S A Date: 2011-07-11 Impact factor: 11.205